During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

To our knowledge, CONTACT-02 is the first phase 3 study of a tyrosine kinase inhibitor-immune checkpoint inhibitor combination to show a significant improvement in progression-free survival in ...

A storm survey conducted by the National Weather Service confirms winds from an EF-1 tornado are what brought down the trees ...

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell ...

Novel combination of acimtamig and an allogenic natural killer cell product shows safety and promising objective response rates in patients with few other remaining treatment choices.

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

Adding an ICI to neoadjuvant chemotherapy can improve pCR rates and may improve OS in patients with MIBC, research suggests.

The Razr+ 2025's displays are one of the areas where the phone does an obvious balancing act between the 'entry-level' Razr ...

Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 ...

News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2025 /CNW/ — News Commentary – The costs ...